SCHEMBL3758796

SCHEMBL3758796

NC(=O)C(=O)N1CCN(C(=O)c2c(Cl)cccc2Cl)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.65
GLA P06280 1/20 0.65
HPGD P15428 1/20 0.65
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
KDM4E B2RXH2 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
P2RX7 Q99572 1/20 0.44
RAB9A P51151 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
SPR P35270 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762762 0.82 RAB9A (0.65) HPGDKMT2AMEN1KDM4EHSD17B10
SCHEMBL3757672 0.80 LMNA (0.67) HPGDKMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL3758799 0.79 NPC1 (0.63) NPC1GLAHPGDKMT2AMEN1
SCHEMBL23064287 0.77 GAA (0.67) NPC1GLAHPGDKMT2AMEN1
SCHEMBL7446407 0.76 HPGD (0.69) NPC1GLAHPGDKMT2AMEN1
SCHEMBL6807257 0.76 NPC1 (0.69) NPC1GLAHPGDKMT2AMEN1
SCHEMBL13198827 0.75 NPC1 (0.67) NPC1GLAHPGDKMT2AMEN1
SCHEMBL9126813 0.74 HPGD (0.71) NPC1GLAHPGDKMT2AMEN1
SCHEMBL3757793 0.74 HPGD (0.61) HPGDKMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL7311576 0.73 RAB9A (0.69) NPC1GLAHPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842696-B2 Piperazine derivatives as inhibitors of stearoyl-CoA desaturase FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-11-30 US claimed
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-03 US claimed
US-7842696-B2 Piperazine derivatives as inhibitors of stearoyl-CoA desaturase FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-11-30 US disclosed
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-03 US disclosed
WO-2008157844-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221583-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 NPC1 206/4885GLA 2878/4885HPGD 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.